Biogen Inc to Discuss the Approval of ADUHELM Call Transcript
Good morning. My name is Jennifer, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen ADUHELM webcast. (Operator Instructions)
I would now like to turn the conference over to Mr. Mike Hencke, Director, Investor Relations. Mr. Hencke, you may begin your conference.
Good morning, and welcome to today's conference call to discuss the approval of aducanumab-avwa or ADUHELM. I encourage everyone to go to the Investors section of biogen.com to find slides that will accompany the discussion related to this call.
ADUHELM is indicated for the treatment of Alzheimer's disease. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial or trials. ADUHELM can cause serious side effects, including amyloid-related imaging abnormalities or ARIA. ARIA is a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |